Characterizing Major Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Pharmacovigilance Study of 27 467 Patients Taking Rivaroxaban

Antiplatelet Therapy for Stable Coronary Artery Disease in Atrial Fibrillation Patients Taking an Oral Anticoagulant

(2014) Morten Lamberts et al.   CIRCULATION

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary

(2014) Craig T. January et al.   CIRCULATION

The Clinical Profile and Pathophysiology of Atrial Fibrillation

(2014) Jason Andrade et al.   CIRCULATION RESEARCH

Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial

(2014) J. P. Piccini et al.   EUROPEAN HEART JOURNAL

Factors Associated With Major Bleeding Events

(2013) Shaun G. Goodman et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

An automated database case definition for serious bleeding related to oral anticoagulant use

(2011) Andrew Cunningham et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Stroke Prevention in Atrial Fibrillation

(2010) Jonathan Mant et al.   DRUGS & AGING

Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty

(2010) Michael Rud Lassen et al.   THROMBOSIS AND HAEMOSTASIS

Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach

(2009) Gregory Y.H. Lip et al.   CHEST

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE